Highlight Therapeutics
4 clinical trials · Sponsor
◉ Watch Highlight Therapeutics
| Record | Firm | Date |
|---|---|---|
| Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) (NCT06422936) | Highlight Therapeutics | 2024-05-27 |
| BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (NCT04570332) | Highlight Therapeutics | 2020-12-30 |
| Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis (NCT04508140) | Highlight Therapeutics | 2020-06-17 |
| Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors (NCT02828098) | Highlight Therapeutics | 2016-06-01 |
Track Highlight Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.